Among the questions UAE-based researchers raise most often about tesamorelin protocol design, injection timing sits near the top — and for a reason that separates this peptide from simpler compounds. Because tesamorelin operates upstream of GH secretion (it is a GHRH analog that tells the pituitary to fire, rather than a direct GH secretagogue like a GH injection), its interaction with the body's endogenous circadian GH architecture is non-trivial. Get the timing right and you are working with the rhythm. Get it wrong and you may be pushing against it.
This research brief synthesizes what the pivotal clinical investigations actually did, examines the mechanistic arguments on both sides, and gives UAE-based investigators the practical information they need to design a coherent protocol before they order tesamorelin from REVIVE LAB UAE.
Endogenous growth hormone is not secreted continuously — it is released in discrete pulses, typically 6-12 per 24 hours in healthy adults, with amplitude that varies sharply across the day. The single largest pulse occurs during slow-wave (deep) sleep, roughly 60-90 minutes after sleep onset, driven by a surge in hypothalamic GHRH activity that coincides with the nocturnal nadir of somatostatin tone. This is not trivial: in younger adults, the nocturnal sleep pulse can account for up to 70% of the entire 24-hour GH secretory output.
Several hormonal dynamics interact with this rhythm:
Tesamorelin's mechanism sits precisely inside this system: as a trans-3-hexenoyl-modified analog of GHRH 1-44, it binds pituitary GHRH receptors, stimulates GH synthesis and release, and does so in a pulsatile pattern rather than the supraphysiologic continuous suppression associated with exogenous GH therapy. The N-terminal modification resists DPP-IV cleavage, extending the effective receptor-engagement window versus native GHRH. But fundamentally, its output depends on the pituitary's readiness to respond — which is circadian, sleep-gated, and somatostatin-modulated.
Before analyzing the AM versus PM debate, it is worth anchoring in what the published evidence base actually did. All four major randomized controlled investigations of tesamorelin used standardized morning administration.
The Falutz 2007 NEJM trial — 412 subjects with HIV-associated lipodystrophy, the largest tesamorelin RCT to date — administered tesamorelin 2 mg subcutaneously once daily in the morning before breakfast or after a light meal. Over 26 weeks, the tesamorelin group showed a 15-18% reduction in visceral adipose tissue (VAT) versus placebo, with a parallel ~50% rise in IGF-1 from baseline. The 2010 26-week extension (Falutz et al., JCEM) maintained the same AM-dosing protocol and confirmed the VAT benefit was sustained, with IGF-1 remaining elevated above baseline throughout. No dose-timing arms were compared; the AM convention was operationally fixed across both trials.
Stanley and colleagues at Massachusetts General Hospital extended the tesamorelin evidence base into HIV-associated non-alcoholic fatty liver disease (NAFLD). The Stanley 2014 JAMA study used tesamorelin 2 mg/day, again administered in the morning, and demonstrated a 32% reduction in liver fat relative to placebo over 12 months — a finding that added a metabolically independent endpoint to the VAT data from Falutz. The Stanley 2019 Lancet HIV 12-month NAFLD study replicated this morning-dosing design. Across all four major trials, the AM window is the documented research-context standard.
| Study | Dose | Dosing Time | Primary Endpoint | Key Finding |
|---|---|---|---|---|
| Falutz 2007 (NEJM) | 2 mg/day SC | Morning (AM) | VAT by CT scan | VAT −15-18%, IGF-1 +~50% |
| Falutz 2010 (JCEM) | 2 mg/day SC | Morning (AM) | VAT 26-wk extension | VAT reduction sustained |
| Stanley 2014 (JAMA) | 2 mg/day SC | Morning (AM) | Liver fat by MRS | Liver fat −32% vs placebo |
| Stanley 2019 (Lancet HIV) | 2 mg/day SC | Morning (AM) | NAFLD fibrosis markers | 12-month NAFLD benefit confirmed |
The AM protocol has mechanistic support beyond simply "that is what the trials did." Several overlapping rationales favor a morning window, typically 30-60 minutes before the first meal:
Overnight fasting means insulin levels are at or near their nadir when the researcher wakes. Low insulin correlates with higher GH receptor sensitivity and reduced somatostatin-driven GH inhibition. Administering tesamorelin into this window means the pituitary encounters a GHRH stimulus when it is relatively unencumbered by the insulin-mediated suppression that characterizes postprandial states. The Falutz trials conducted AM dosing pre-breakfast or after a very light meal for this reason.
After the large nocturnal GH pulse, IGF-1 rises through the early morning hours. By mid-morning, IGF-1 may be near its daily peak — which would create negative feedback on GHRH receptor responsiveness. Early AM administration (6-8 AM) captures the moment between IGF-1's nocturnal rise still building and the full negative-feedback suppression that follows a few hours later.
Cortisol peaks at approximately 6-8 AM (the cortisol awakening response). Administering tesamorelin very early — at waking, before the cortisol peak fully establishes — allows some investigators to attempt a brief cortisol-trough window. Others push AM dosing to 9-10 AM, accepting elevated morning cortisol, noting that the VAT-reduction endpoint in the Falutz/Stanley trials was robust despite the cortisol overlap. The clinical evidence suggests the AM cortisol environment does not eliminate tesamorelin's metabolic efficacy over a 26-week research horizon.
A separate and growing area of research-community discussion centers on pre-sleep tesamorelin administration — typically 30-60 minutes before bed — with the explicit goal of amplifying the dominant nocturnal GH pulse rather than creating an independent daytime pulse.
The largest endogenous GH pulse occurs 60-90 minutes after sleep onset, coinciding with the first deep slow-wave sleep cycle. Somatostatin tone is at its daily nadir during this window, meaning the pituitary is maximally receptive to GHRH-type stimulation. Administering tesamorelin 30-60 minutes before bed positions the exogenous GHRH analog to arrive at the pituitary roughly as the subject enters Stage 3 sleep — layering the peptide stimulus on top of the physiological GHRH surge and the somatostatin-withdrawal effect simultaneously.
PM and pre-sleep administration places tesamorelin's GH-stimulatory effect at the moment of maximum cortisol distance — the late evening is the daily cortisol nadir. This temporal separation may allow the resulting GH pulse (and downstream IGF-1 generation) to operate with less counter-regulatory interference than AM dosing, at least during the acute overnight window. Whether this translates to a measurably different long-term VAT or liver-fat endpoint has not been studied in RCT format.
The mechanistic argument for PM dosing carries one practical consideration: a tesamorelin-amplified nocturnal GH pulse means elevated IGF-1 will be present during the morning hours. For some research designs — particularly those evaluating daytime metabolic parameters — this may be the intended profile. For protocols that need stable fasting IGF-1 measurements taken in the morning, AM dosing produces a more predictable measurement window.
| Factor | AM Injection (6-10 AM) | PM / Pre-Sleep Injection (9-11 PM) |
|---|---|---|
| Published trial precedent | All 4 major RCTs (Falutz, Stanley) | No RCT data available |
| Cortisol environment | Rising / peak cortisol (partial antagonism) | Cortisol nadir (minimal antagonism) |
| Somatostatin tone | Moderate daytime tone | Nadir during slow-wave sleep (permissive) |
| Fasting / insulin state | Overnight fast, low insulin | Post-dinner, variable insulin depending on meal timing |
| GH pulse targeted | Independent daytime pulse | Amplification of dominant nocturnal pulse |
| IGF-1 morning measurement | Cleaner baseline for AM blood draw | May show elevated IGF-1 from overnight pulse |
| Protocol reproducibility | High (trial-validated, consistent timing easy) | Moderate (sleep onset variability affects timing) |
The clinical evidence base was built on AM dosing, and that remains the most defensible protocol position for any investigator who needs their work to sit within the Falutz and Stanley methodological framework. The IGF-1 endpoints, the VAT reduction data (−15-18% over 26 weeks), and the liver fat findings (−32% at 12 months) are all associated with morning administration at 1-2 mg/day research-context dosing. Investigators looking to match their design to peer-reviewed precedent should default to AM.
The PM / pre-sleep argument is mechanistically coherent but remains hypothesis-generating rather than trial-validated. Several considerations push researchers toward exploring it nonetheless:
Regardless of timing window, the operational protocol for tesamorelin reconstitution is standardized. REVIVE LAB UAE stocks tesamorelin 5 mg and 10 mg vials. The research-context dose range documented across the Falutz and Stanley trials is 1-2 mg per day. The table below covers the most common reconstitution configurations for UAE-based researchers:
| Vial Size | BAC Water Added | Concentration | Volume per 1 mg Dose | Volume per 2 mg Dose |
|---|---|---|---|---|
| Tesamorelin 5 mg | 2.5 mL | 2 mg / mL | 0.5 mL (50 IU) | 1.0 mL (100 IU) |
| Tesamorelin 5 mg | 1.0 mL | 5 mg / mL | 0.2 mL (20 IU) | 0.4 mL (40 IU) |
| Tesamorelin 10 mg | 5.0 mL | 2 mg / mL | 0.5 mL (50 IU) | 1.0 mL (100 IU) |
| Tesamorelin 10 mg | 2.0 mL | 5 mg / mL | 0.2 mL (20 IU) | 0.4 mL (40 IU) |
Reconstituted vials should be stored at 2-8°C and used within 14 days. Reconstitute slowly by directing the bacteriostatic water down the inner glass wall of the vial, not directly onto the lyophilized cake, and swirl gently rather than shaking. For a standard 5 mg vial at a 1 mg/day research-context dose, the vial covers a 5-day window post-reconstitution. The 10 mg format is preferred for longer continuous protocols to reduce reconstitution frequency and minimize sterility risk from repeated vial penetration.
REVIVE LAB UAE supplies HPLC-verified, lot-COA, cold-chain dispatched tesamorelin across all 7 emirates. Whether you are running an AM or PM protocol, the supply chain requirement is the same: cold, verified, in-hand without a 2-week international shipping wait that burns your reconstitution window before you even start. Here is the current delivery framework for researchers looking to buy tesamorelin UAE:
| Location | Delivery Window | Cash on Delivery |
|---|---|---|
| Dubai (Marina, JBR, DIFC, Business Bay, JVC, Downtown, Palm, Jumeirah) | Same-day, 4-8 hours | Yes |
| Abu Dhabi (Corniche, Yas, Saadiyat, Reem Island) | Next-day, 18-24 hours | Yes |
| Sharjah | Same-day / next-day, 8-18 hours | Yes |
| Ajman | Next-day, 18-24 hours | Yes |
| Ras Al Khaimah (RAK) | Next-day, 18-24 hours | Yes |
| Fujairah | Next-day, 24 hours | Yes |
| Umm Al Quwain (UAQ) | Next-day, 18-24 hours | Yes |
All shipments are dispatched in validated cold-chain insulation, maintaining 2-8°C through the UAE summer. Packaging is plain and unbranded by default. Tesamorelin 5 mg and 10 mg vials are in stock UAE today — no pre-order, no international lead time. For researchers in Dubai Marina, JBR, Business Bay, JVC, DIFC, Palm Jumeirah, Downtown or Jumeirah, ordering before the daily cut-off means vials arrive the same evening, cold and ready to reconstitute on your schedule — AM or PM.
Published clinical trials — including the Falutz 2007 and 2010 NEJM / JCEM studies and the Stanley 2014 JAMA and 2019 Lancet HIV studies — administered tesamorelin at a consistent time each day in the morning, establishing AM dosing as the evidence-based research standard. The AM window aligns with the post-fast, low-insulin state and avoids direct overlap with the dominant nocturnal GH pulse, producing a discrete daytime GH stimulus. PM / pre-sleep dosing has a mechanistic rationale centered on somatostatin nadir and nocturnal pulse amplification, but no RCT data has validated this approach against metabolic endpoints. Investigators seeking to align their protocol with the Falutz / Stanley evidence base should use AM administration at a consistent daily time.
Yes. REVIVE LAB UAE supplies HPLC-verified, lot-COA, cold-chain dispatched tesamorelin across all 7 emirates. Same-day delivery is available for researchers in Dubai — including Dubai Marina, JBR, Business Bay, JVC, DIFC, Downtown, Palm Jumeirah and Jumeirah — for orders placed before the daily cut-off. Abu Dhabi, Sharjah, Ajman, RAK, Fujairah and UAQ receive next-day delivery within 24 hours. Cash on delivery Dubai is supported and all shipments use discreet, unbranded outer packaging as the default.
REVIVE LAB UAE stocks tesamorelin in 5 mg and 10 mg vials — the formats used in the major clinical studies. The research-context dosing referenced in the Falutz and Stanley trial literature is 1 mg to 2 mg per day via subcutaneous injection. REVIVE LAB UAE does not stock 1 mg or 2 mg vials; the 5 mg and 10 mg formats are the in-stock options available for same-day dispatch in Dubai and tesamorelin 24h delivery across the UAE. Both vial sizes are HPLC-tested to ≥99% purity, shipped with full lot COA documentation available on request.